Maryam Mohammadi‐Khanaposhtani

ORCID: 0000-0001-7664-9664
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Synthesis and biological activity
  • Natural Antidiabetic Agents Studies
  • Cholinesterase and Neurodegenerative Diseases
  • Click Chemistry and Applications
  • Carbohydrate Chemistry and Synthesis
  • Synthesis and Characterization of Heterocyclic Compounds
  • Computational Drug Discovery Methods
  • Enzyme function and inhibition
  • Multicomponent Synthesis of Heterocycles
  • Phenothiazines and Benzothiazines Synthesis and Activities
  • Diet, Metabolism, and Disease
  • Microbial Applications in Construction Materials
  • Quinazolinone synthesis and applications
  • Synthesis and Biological Evaluation
  • Biochemical and Molecular Research
  • HIV/AIDS drug development and treatment
  • Bioactive Compounds and Antitumor Agents
  • Cancer therapeutics and mechanisms
  • Peptidase Inhibition and Analysis
  • Synthesis of Organic Compounds
  • Phytochemicals and Antioxidant Activities
  • Synthesis of heterocyclic compounds
  • Pancreatic function and diabetes
  • Pesticide Exposure and Toxicity
  • Synthesis and Reactivity of Heterocycles

Babol University of Medical Sciences
2018-2025

Tehran University of Medical Sciences
2015-2022

Auckland University of Technology
2019

Institute for Health Metrics and Evaluation
2018-2019

University of Washington
2019

Iran University of Medical Sciences
2017

Shahid Beheshti University
2008-2009

Emma Nichols Cassandra Szoeke Dan J. Stein Nooshin Abbasi Foad Abd-Allah and 95 more Jemal Abdela Miloud Taki Eddine Aichour Rufus Akinyemi Fares Alahdab Solomon Weldegebreal Asgedom Ashish Awasthi Suzanne Barker‐Collo Bernhard T. Baune Yannick Béjot Abate Bekele Belachew Derrick Bennett Belete Biadgo Ali Bijani Muhammad Shahdaat Bin Sayeed Carol Brayne David O. Carpenter Félix Carvalho Ferrán Catalá-López Ester Cerin Jee-Young J Choi Anh Kim Dang Meaza Girma Degefa Shirin Djalalinia Manisha Dubey Eyasu Ejeta Duken David Edvardsson Matthias Endres Sharareh Eskandarieh André Faro Farshad Farzadfar Seyed-Mohammad Fereshtehnejad Eduarda Fernandes Irina Filip Florian Fischer Abadi Kahsu Gebre Demeke Geremew Maryam Ghasemi‐Kasman E. V. Gnedovskaya Rajeev Gupta Vladimir Hachinski Tekleberhan B Hagos Samer Hamidi Graeme J. Hankey Josep María Haro Simon I Hay Seyed Sina Naghibi Irvani Ravi Prakash Jha Jost B. Jonas Rizwan Suliankatchi Abdulkader André Karch Amir Kasaeian Yousef Khader Fakher Rahim Ejaz Ahmad Khan Tripti Khanna Tawfik Khoja Jagdish Khubchandani Adnan Kısa Katarzyna Kissimova‐Skarbek Mika Kivimäki Ai Koyanagi Kristopher J Krohn Giancarlo Logroscino Stefan Lorkowski Marek Majdán Reza Malekzadeh Winfried März João Massano Getnet Mengistu Atte Meretoja Moosa Mohammadi Maryam Mohammadi‐Khanaposhtani Ali H. Mokdad Stefania Mondello Ghobad Moradi Gabriele Nagel Mohsen Naghavi Gurudatta Naik Long Hoang Nguyen Trang Huyen Nguyen Yirga Legesse Nirayo Molly R Nixon Richard Ofori‐Asenso Felix Akpojene Ogbo Andrew T Olagunju Mayowa Owolabi Songhomitra Panda‐Jonas Valéria Maria de Azeredo Passos David M. Pereira Gabriel David Pinilla-Monsalve М. А. Пирадов Constance D Pond Hossein Poustchi Mostafa Qorbani Amir Radfar

BackgroundThe number of individuals living with dementia is increasing, negatively affecting families, communities, and health-care systems around the world. A successful response to these challenges requires an accurate understanding disease burden. We aimed present first detailed analysis global prevalence, mortality, overall burden as captured by Global Burden Diseases, Injuries, Risk Factors (GBD) Study 2016, highlight most important messages for clinicians neurologists.MethodsGBD 2016...

10.1016/s1474-4422(18)30403-4 article EN cc-by The Lancet Neurology 2018-11-26

Abstract Coumarins and their derivatives are receiving increasing attention due to numerous biochemical pharmacological applications. In this study, a series of novel coumarin–1,2,3‐triazole‐acetamide hybrids was tested against some metabolic enzymes including α‐glycosidase (α‐Gly), α‐amylase (α‐Amy), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), human carbonic anhydrase I (hCA I), hCA II. The new showed K i values in the range 483.50–1,243.04 nM I, 508.55–1,284.36 II,...

10.1002/ardp.202000109 article EN Archiv der Pharmazie 2020-07-09

In this study, novel acridone‐1,2,4‐oxadiazole‐1,2,3‐triazole hybrids were designed, synthesized, and evaluated for their acetylcholinesterase butyrylcholinesterase inhibitory activity. Among various synthesized compounds, 10‐((1‐((3‐(4‐methoxyphenyl)‐1,2,4‐oxadiazol‐5‐yl)methyl)‐1 H ‐1,2,3‐triazol‐4‐yl)methyl)acridin‐9(10 )‐one 10b showed the most potent anti‐acetylcholinesterase activity (IC 50 = 11.55 μ m ) being as rivastigmine. Also docking outcomes in good agreement with vitro results...

10.1111/cbdd.12609 article EN Chemical Biology & Drug Design 2015-06-16

Herein, novel coumarin-pyridine derivatives<bold>4a–p</bold>as potent α-glucosidase inhibitors were synthesized by a one-pot and three-component synthesis method.

10.1039/c8nj02495b article EN New Journal of Chemistry 2018-01-01

Abstract In this study, 18 novel quinoline-based-benzo[d]imidazole derivatives were synthesized and screened for their α-glucosidase inhibitory potential. All compounds in the series except 9q showed a significant inhibition with IC 50 values range of 3.2 ± 0.3–185.0 0.3 µM, as compared to standard drug acarbose (IC = 750.0 5.0 µM). A kinetic study indicated that compound 9d most potent derivative against was competitive type inhibitor. Furthermore, molecular docking revealed effective...

10.1038/s41598-022-18455-7 article EN cc-by Scientific Reports 2022-08-18

Abstract In the present work, a new series of 14 novel phthalimide-benzenesulfonamide derivatives 4a – n were synthesized, and their inhibitory activity against yeast α-glucosidase was screened. The obtained results indicated that most newly synthesized compounds showed prominent α-glucosidase. Among them, 4-phenylpiperazin derivative 4m exhibited strongest inhibition with IC 50 value 52.2 ± 0.1 µM. Enzyme kinetic study compound proved its mode competitive K i this calculated to be 52.7...

10.1038/s41598-022-14896-2 article EN cc-by Scientific Reports 2022-06-22

Abstract The control of postprandial hyperglycemia is an important target in the treatment type 2 diabetes mellitus (T2DM). As a result, targeting α-glucosidase as most enzyme breakdown carbohydrates to glucose that leads increase one processes T2DM. In present work, new class benzimidazole-Schiff base hybrids 8a–p has been developed based on potent reported inhibitors. These compounds were synthesized by sample recantations, characterized 1 H-NMR, 13 C-NMR, FT-IR, and CHNS elemental...

10.1038/s41598-022-18896-0 article EN cc-by Scientific Reports 2022-09-01
Coming Soon ...